ESPR has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
ESPR has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
As of today (2024-04-27), Esperion Therapeutics's current share price is $1.90. Esperion Therapeutics's Cyclically Adjusted Revenue per Share for the quarter that ended in Dec. 2023 was $4.24. Esperion Therapeutics's Cyclically Adjusted PS Ratio for today is 0.45.
The historical rank and industry rank for Esperion Therapeutics's Cyclically Adjusted PS Ratio or its related term are showing as below:
During the past years, Esperion Therapeutics's highest Cyclically Adjusted PS Ratio was 13.38. The lowest was 0.18. And the median was 1.71.
ESPR's Cyclically Adjusted PS Ratio is ranked better thanThe Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.
Esperion Therapeutics's adjusted revenue per share data for the three months ended in Dec. 2023 was $0.287. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is $4.24 for the trailing ten years ended in Dec. 2023.
The historical data trend for Esperion Therapeutics's Cyclically Adjusted PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Esperion Therapeutics Quarterly Data | ||||||||||||||||||||
Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | |
Cyclically Adjusted PS Ratio | Get a 7-Day Free Trial | 1.28 | 0.34 | 0.30 | 0.22 | 0.70 |
For the Drug Manufacturers - Specialty & Generic subindustry, Esperion Therapeutics's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Drug Manufacturers industry and Healthcare sector, Esperion Therapeutics's Cyclically Adjusted PS Ratio distribution charts can be found below:
* The bar in red indicates where Esperion Therapeutics's Cyclically Adjusted PS Ratio falls into.
Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.
The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.
Esperion Therapeutics's Cyclically Adjusted PS Ratio for today is calculated as
Cyclically Adjusted PS Ratio | = | Share Price | / | Cyclically Adjusted Revenue per Share |
= | 1.90 | / | 4.24 | |
= | 0.45 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Esperion Therapeutics's Cyclically Adjusted Revenue per Share for the quarter that ended in Dec. 2023 is calculated as:
For example, Esperion Therapeutics's adjusted Revenue per Share data for the three months ended in Dec. 2023 was:
Adj_RevenuePerShare | = | Revenue per Share | / | CPI of Dec. 2023 (Change) | * | Current CPI (Dec. 2023) |
= | 0.287 | / | 129.4194 | * | 129.4194 | |
= | 0.287 |
Current CPI (Dec. 2023) = 129.4194.
Esperion Therapeutics Quarterly Data
Revenue per Share | CPI | Adj_RevenuePerShare | |
201403 | 0.000 | 99.695 | 0.000 |
201406 | 0.000 | 100.560 | 0.000 |
201409 | 0.000 | 100.428 | 0.000 |
201412 | 0.000 | 99.070 | 0.000 |
201503 | 0.000 | 99.621 | 0.000 |
201506 | 0.000 | 100.684 | 0.000 |
201509 | 0.000 | 100.392 | 0.000 |
201512 | 0.000 | 99.792 | 0.000 |
201603 | 0.000 | 100.470 | 0.000 |
201606 | 0.000 | 101.688 | 0.000 |
201609 | 0.000 | 101.861 | 0.000 |
201612 | 0.000 | 101.863 | 0.000 |
201703 | 0.000 | 102.862 | 0.000 |
201706 | 0.000 | 103.349 | 0.000 |
201709 | 0.000 | 104.136 | 0.000 |
201712 | 0.000 | 104.011 | 0.000 |
201803 | 0.000 | 105.290 | 0.000 |
201806 | 0.000 | 106.317 | 0.000 |
201809 | 0.000 | 106.507 | 0.000 |
201812 | 0.000 | 105.998 | 0.000 |
201903 | 5.111 | 107.251 | 6.167 |
201906 | 0.036 | 108.070 | 0.043 |
201909 | 0.036 | 108.329 | 0.043 |
201912 | 0.036 | 108.420 | 0.043 |
202003 | 0.067 | 108.902 | 0.080 |
202006 | 7.356 | 108.767 | 8.753 |
202009 | 0.138 | 109.815 | 0.163 |
202012 | 0.359 | 109.897 | 0.423 |
202103 | 0.307 | 111.754 | 0.356 |
202106 | 1.550 | 114.631 | 1.750 |
202109 | 0.545 | 115.734 | 0.609 |
202112 | 0.417 | 117.630 | 0.459 |
202203 | 0.309 | 121.301 | 0.330 |
202206 | 0.298 | 125.017 | 0.308 |
202209 | 0.280 | 125.227 | 0.289 |
202212 | 0.256 | 125.222 | 0.265 |
202303 | 0.310 | 127.348 | 0.315 |
202306 | 0.236 | 128.729 | 0.237 |
202309 | 0.304 | 129.860 | 0.303 |
202312 | 0.287 | 129.419 | 0.287 |
Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.
Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.
Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.
If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.
Thank you for viewing the detailed overview of Esperion Therapeutics's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.
Eric Warren | officer: Chief Commercial Officer | 3891 RANCHERO DRIVE, SUITE 150, ANN ARBOR MI 48108 |
J Martin Carroll | director | C/O CATALENT, INC., 14 SCHOOLHOUSE ROAD, SOMERSET NJ 08873 |
Stephen Rocamboli | director | C/OPARMOUNT CAPITAL, 787 SEVENTH AVE 48TH FL, NEW YORK NY 10019 |
Sheldon L. Koenig | officer: Chief Operating Officer | C/O PORTOLA PHARMACEUTICALS, INC., 270 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080 |
Joanne M. Foody | officer: Chief Medical Officer | C/O ESPERION THERAPEUTICS, INC., 3891 RANCHERO DRIVE, SUITE 150, ANN ARBOR MI 48108 |
Benjamin Looker | officer: General Counsel | C/O TRILLIUM THERAPEUTICS INC., 2488 DUNWIN DRIVE, MISSISSAUGA A6 L5L 1J9 |
Benjamin Halladay | officer: Chief Financial Officer | ESPERION THERAPEUTICS, INC., 3891 RANCHERO DRIVE, SUITE 150, ANN ARBOR MI 48108 |
Fischer Seth H.z. | director | C/O TRIUS THERAPEUTICS, INC., 6310 NANCY RIDGE DRIVE, SUITE 101, SAN DIEGO CA 92121 |
Biotech Target N V | 10 percent owner | ARA HILL TOP BUILDING, UNIT A-5, PLETTERIJWEG OOST 1, CURACAO, WILLEMSTAD P8 000000 |
Alan Fuhrman | director | C/O AMBIT BIOSCIENCES CORPORATION, 11080 ROSELLE STREET, SAN DIEGO CA 92121 |
Timothy M Mayleben | director, officer: Pres & Chief Executive Officer | 3621 SOUTH STATE ST, 695 KMS PL, ANN ARBOR MI 48108 |
Ashley Hall | officer: Chief Development Officer | C/O ESPERION THERAPEUTICS INC., 3891 RANCHERO DRIVE SUITE 150, ANN ARBOR MI 48108 |
Tracy M Woody | director | 2656 CROSSPARK ROAD, SUITE 100, CORALVILLE IA 52241 |
Richard Bartram | officer: Chief Financial Officer | C/O ESPERION THERAPEUTICS, INC., 3891 RANCHERO DRIVE, SUITE 150, ANN ARBOR MI 48108 |
Nicole Vitullo | director, 10 percent owner | 3030 SCIENCE PARK ROAD, SAN DIEGO CA 92121 |
From GuruFocus
By GuruFocus Research • 11-07-2023
By GlobeNewswire • 08-26-2023
By GlobeNewswire • 06-24-2023
By sperokesalga sperokesalga • 05-12-2023
By GlobeNewswire • 11-11-2023
By Marketwired • 08-28-2023
By Marketwired • 08-26-2023
By Marketwired • 08-01-2023
By Marketwired • 08-08-2023
By sperokesalga sperokesalga • 06-05-2023